Who is sponsoring NCT00892736?

NCT00892736 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT00892736?

Interventions in NCT00892736: Laboratory Biomarker Analysis, Pharmacological Study, Veliparib.

What condition does NCT00892736 study?

NCT00892736 studies Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma.

Is NCT00892736 still recruiting?

NCT00892736 is currently completed. Last updated 29 June 2018.

Last reviewed 2018-06-29 · How we verify

NCT00892736

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Completed Phase 1 Last updated 29 June 2018

What this trial tests

Phase 1 trial testing Laboratory Biomarker Analysis in Basal-Like Breast Carcinoma in 98 participants. Completed in 19 May 2017.

Timeline

20 April 2009

Primary endpoint
19 May 2017

19 May 2017

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	98
Start date	20 April 2009
Primary completion	19 May 2017
Estimated completion	19 May 2017
Sites	7 locations across United States

Drugs / interventions tested

Laboratory Biomarker Analysis — full drug profile →
Pharmacological Study — full drug profile →
Veliparib — full drug profile →

Conditions studied

Basal-Like Breast Carcinoma — all drugs for Basal-Like Breast Carcinoma →
BRCA1 Mutation Carrier — all drugs for BRCA1 Mutation Carrier →
BRCA2 Mutation Carrier — all drugs for BRCA2 Mutation Carrier →
Breast Carcinoma — all drugs for Breast Carcinoma →

Sponsor

National Cancer Institute (NCI)

Who can join

19 and older, any sex, with Basal-Like Breast Carcinoma or BRCA1 Mutation Carrier. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Regulated cell death (RCD) in cancer: key pathways and targeted therapies.
Peng F, Liao M, Qin R, Zhu S, et al · · 2022 · cited 586× · PMID 35963853 · DOI 10.1038/s41392-022-01110-y
Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research.
Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, et al · · 2012 · cited 371× · PMID 22198208 · DOI 10.1016/j.canlet.2011.12.025
Targeting DNA damage response in cancer therapy.
Hosoya N, Miyagawa K. · · 2014 · cited 232× · PMID 24484288 · DOI 10.1111/cas.12366
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease.
Nguyen TT, Wei S, Nguyen TH, Jo Y, et al · · 2023 · cited 221× · PMID 37612409 · DOI 10.1038/s12276-023-01046-5
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
Zhu H, Wei M, Xu J, Hua J, et al · · 2020 · cited 203× · PMID 32122376 · DOI 10.1186/s12943-020-01167-9
Harnessing synthetic lethal interactions in anticancer drug discovery.
Chan DA, Giaccia AJ. · · 2011 · cited 195× · PMID 21532565 · DOI 10.1038/nrd3374
PARP inhibitors in the management of breast cancer: current data and future prospects.
Livraghi L, Garber JE. · · 2015 · cited 188× · PMID 26268938 · DOI 10.1186/s12916-015-0425-1
PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. · · 2017 · cited 161× · PMID 29037806 · DOI 10.1016/j.ygyno.2017.10.003

Verify or expand the search:

Other trials of Laboratory Biomarker Analysis

Trials testing the same drug.

NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00892736 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 29 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00892736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing